Roche’s Alecensa fast-tracked in China
China has become more accepting of Western medicines and sees the value of a strong patenting process, opening the door for more foreign trade and mutual benefits.
The factors shaping the healthcare landscape in emerging markets.
Novo expects Victoza and semaglutide to gain momentum.
Innovative channels now take 60% of share compared with traditional channels for medical communication in China, reports Adele Li of Kantar Health, and doctors’ willingness to engage with pharma companies online is a cause for optimism for those working in the region. Read the full article in the latest edition of pharmaphorum’s Deep Dive: Digital magazine.